The Ebola virus disease first appeared in 1976 in the Sudan and the Democratic Republic of Congo. The most recent outbreak occurred in West Africa in March 2014 and quickly spread in surrounding countries. Ebola spreads through direct contact with the body fluids of an infected individual. The incubation period for Ebola is 2 to 21 days. Individuals are infectious when symptomatic. Identifying individuals at high risk for Ebola in the United States includes early recognition of symptoms and a history of travel to an Ebola-affected area. Multiple diagnostic tests exist and should include a complete blood count and a comprehensive metabolic profile. Standard, contact, and droplet precautions are advised when taking care of patients with Ebola. Appropriate personal protective equipment as recommended by the Centers for Disease Control and Prevention should be worn. No vaccine or antiviral drug has been approved, but vaccine trials are under way. Occupational health nurses play a key role in educating employees about this disease.
The U.S. Department of Health and Human Services (HHS) said on Wednesday it will fund the manufacturing of Merck&Co Inc's investigational Ebola vaccine called V920, in response to the outbreak of the deadly virus in the Democratic Republic of the Congo (DRC).
Health workers inside a "CUBE" talk to an Ebola patient, while a nurse consults a chart outside. ALIMA Ebola Treatment Centre, Beni, Democratic Republic of the Congo. Two drugs have been found to successfully treat the Ebola virus. Aid agencies have welcomed the news saying it allows communities to access early treatment. Courtesy: World Health Organisation (WHO)By Issa Sikiti da SilvaCOTONOU, Benin, Aug 20 2019 (IPS) While people in the Democratic Republic of Congo (DRC) are slowly being made aware that scientists have discovered two drugs that are effective in treating Ebola, letting go of the fear and anxiety ...
A year into an Ebola outbreak in the Democratic Republic of the Congo (DRC), researchers have halted an experimental drug trial there because early results appear so promising. The drugs will be made available to more patients in the DRC, hopefully saving lives as the current outbreak continues. But the decision to end the trial early has implications that go beyond the DRC: it could also change the way infectious disease treatments are studied in years to come. The trial, which began last November and enrolled 681 patients at four sites in the DRC, was meant to test four experimental Ebola therapies: ZMapp (an antibody co...
[The New Humanitarian] Kampala -Uganda has launched its largest trial of a new experimental Ebola vaccine, as rising cases of the deadly virus in neighbouring Democratic Republic of Congo continue to raise fears of a wider regional outbreak.
[The Conversation Africa] The most recent Ebola outbreak in the Democratic Republic of the Congo (DRC) rages on. There's been a continued increase in the number of new cases for a year since the outbreak was first declared. This is despite the extensive use of an experimental vaccine, new treatments and more rapid response to the outbreak when compared to the West African outbreak.
The most expedient way to test Johnson and Johnson's experimental Ebola vaccine is to administer it during an outbreak, which is the way Merck's vaccine was successfully deployed in Guinea in 2015. Locally, however, there are fears people in the Congo could be used as guinea pigs.
[The Conversation Africa] In August 2015 Dr Sakoba Keita, who led the Ebola response in Guinea during the largest Ebola outbreak the world has ever seen, declared:
British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.
ConclusionsOur projections are concentrated in a range up to about 300 cases beyond those already reported. While a catastrophic outbreak is not projected, it is not ruled out, and prevention and vigilance are warranted. Prospective validation of our models in real time allowed us to generate more accurate short-term forecasts, and this process may prove useful for future real-time short-term forecasting. We estimate that transmission rates are higher than would be seen under target levels of 62% coverage due to contact tracing and vaccination, and this model estimate may offer a surrogate indicator for the outbreak response challenges.
The complete TWiV team give a report on the Ebola virus outbreak in DRC, and reveal that cell surface nectin proteins cause the transfer of cytoplasmic cargo, including measles virus, between cells. Click arrow to play Download TWiV 559 (65 MB .mp3, 108 min) Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV!